UOC
ITCI

UBS O'Connor’s Intra-Cellular Therapies Inc. ITCI Stock Holding History

UBS O'Connor’s Portfolio ITCI Stock Details ITCI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-3,091,133
Closed -$408M – 477
2025
Q1 		$408M Buy
3,091,133
+3,070,849
+15,139% +$383M 9.64% 3
2024
Q4 		$1.69M Buy
20,284
+2,941
+17% +$242K 0.04% 177
2024
Q3 		$1.27M Buy
17,343
+343
+2% +$25.8K 0.03% 248
2024
Q2 		$1.16M Buy
+17,000
New +$1.18M 0.03% 274

Other funds holding ITCI

DekaBank Deutsche Girozentrale
DekaBank Deutsche Girozentrale Frankfurt, Germany $60.6B AUM 23.27% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $68.3B AUM 20.5% 1-Year Est. Return
KIM
Kestra Investment Management Austin, Texas $5.8B AUM 14.71% 1-Year Est. Return
HNB
Huntington National Bank Columbus, Ohio $18.1B AUM 24.69% 1-Year Est. Return

UBS O'Connor's ITCI Position: Q2 2025 in Review

UBS O'Connor sold out of Intra-Cellular Therapies Inc. (ITCI) in Q2 2025, closing a stake of 3,091,133 shares — an estimated $408M sold.

UBS O'Connor first reported a position in ITCI in Q2 2024 and held it in 4 quarters. The position peaked at $408M in Q1 2025. 4 funds tracked by Wall St. Rank hold ITCI as of Q2 2025.

  • UBS O'Connor reported no remaining Intra-Cellular Therapies Inc. position as of Q2 2025 after selling out during the quarter.
  • UBS O'Connor sold 3,091,133 Intra-Cellular Therapies Inc. shares in Q2 2025, an estimated $408M.
  • UBS O'Connor first reported a position in Intra-Cellular Therapies Inc. in Q2 2024 and held it in 4 quarters.
  • UBS O'Connor's Intra-Cellular Therapies Inc. position peaked at $408M in Q1 2025.
  • 4 funds tracked by Wall St. Rank held Intra-Cellular Therapies Inc. as of Q2 2025.

Based on UBS O'Connor's 13F filing for Q2 2025, filed 14 Aug 2025.